Infex Therapeutics develops first-in-class drug candidates to address antimicrobial resistance by acquiring and in-licensing early-stage assets and advancing them toward clinical proof of concept. Its lead candidate, RESP-X, has completed a Phase IIa trial targeting Pseudomonas aeruginosa in respiratory patients. The company is also advancing the MET-X resistance-bypass program through a strategic clinical development partnership with Venus Remedies Ltd in India and is progressing preclinical BamA inhibitor programs. Infex is led by CEO Dr. Peter Jackson and chaired by Jon Moulton. The firm is based in Macclesfield, Cheshire, UK and plans to use recent funding to advance these clinical and preclinical programs.

Total raised

$6M

Funding rounds

1

Latest round

Equity

Latest activity

May 2026